Komori
SanBio (4592) · FactAchieved

Eliminating Accumulated Deficits through Reductions in Stated Capital and Capital Reserves

First written in FY2020-Q2. 10 of 19 entries say "Advanced", first in FY2020. Latest entry: FY2027-H1.

19entries
8years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2020 – FY2027-H12019: 220192020: 220202021: 220212022: 220222023: 220232024: 220242025: 220252026: 52026
Same theme, other companies
Capital Policy and Dividend Preparation through Capital Reduction and Deficit EliminationA theme 287 companies write about · 1 as a headwind · 286 as a tailwind

127 other companies' latest entry also says "Achieved".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 289 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2027-H1AchievedAnnual report

    「Based on a resolution at the 13th Annual General Meeting of Shareholders held on 22 April 2026, the Company offset the deficit in retained earnings carried forward effective 5 June 2026, reducing capital and capital surplus by ¥1,704.395 million each and increasing retained earnings by ¥3,408.791 million.」

    The deficit offset, which was at the stage of a board resolution and submission to the shareholders’ meeting in the previous fiscal year, was completed effective 5 June 2026.
  2. FY2026AdvancedAnnual report

    「At a meeting of the Board of Directors held on 17 March 2026, we resolved to submit proposals concerning a reduction in the amounts of capital stock and capital reserves and the disposal of surplus to the 13th Annual General Meeting of Shareholders to be held on 22 April 2026.」

    Regarding the deficit offset, an additional measure progressed to the stage of a board resolution and submission to the shareholders’ meeting, involving reductions of ¥1,704.395 million each in capital and capital reserves and the transfer of ¥3,408.791 million to retained earnings carried forward.
  3. FY2026-H1AchievedAnnual report

    「Based on a resolution at the 12th Annual General Meeting of Shareholders held on 23 April 2025, the Company offset the deficit in retained earnings carried forward effective 6 June 2025, reducing capital and capital surplus by ¥1,772.807 million each and increasing retained earnings by ¥3,545.614 million.」

    The deficit offset through reductions in capital and capital reserves, which was at the submission-to-the-shareholders’-meeting stage in the previous filing, was implemented effective 6 June 2025.
  4. FY2025AdvancedAnnual report

    「At a meeting of the Board of Directors held on 17 March 2025, the Company resolved to submit a proposal concerning reductions in the amounts of capital and capital reserves and the disposal of retained earnings to the 12th Annual General Meeting of Shareholders held on 23 April 2025.」

    Regarding the deficit offset, an additional measure progressed to the stage of submission to the shareholders’ meeting, involving reductions of ¥1,772,807,092 in capital and ¥1,772,807,091 in capital reserves, and the transfer of ¥3,545,614,183 to retained earnings carried forward.
  5. FY2025-Q1AchievedAnnual report

    「Effective 6 June 2024, capital and capital reserves each decreased by ¥2,066.993 million as a result of reductions in capital and capital reserves approved by the shareholders’ meeting.」

    The reductions in capital and capital reserves submitted to the shareholders’ meeting and planned in the previous fiscal year were implemented effective 6 June 2024.
  6. FY2024AdvancedAnnual report

    「At a meeting of the Board of Directors held on 18 March 2024, the Company resolved to submit a proposal concerning reductions in the amounts of capital and capital reserves and the disposal of retained earnings to the 11th Annual General Meeting of Shareholders held on 24 April 2024.」

    Regarding the deficit offset, an additional measure progressed to the stage of submission to the shareholders’ meeting, involving reductions of approximately ¥2.067 billion each in capital and capital reserves, the transfer of approximately ¥4.134 billion to retained earnings carried forward, and the reduction of retained earnings carried forward to ¥0.
  7. FY2024-Q1AchievedAnnual report

    「Effective 6 June 2023, capital and capital reserves each decreased by ¥4,435.693 million as a result of reductions in capital and capital reserves approved by the shareholders’ meeting.」

    The reductions in capital and capital reserves presented in the previous fiscal year as approved and planned at the shareholders’ meeting were implemented effective 6 June 2023.
  8. FY2023AdvancedAnnual report

    「The Company will reduce the amounts of capital and capital reserves to reduce its tax burden, offset the deficit to strengthen its financial position, and secure flexibility in its capital policy, including future shareholder returns through dividends and share repurchases, by reducing capital and capital reserves and disposing of retained earnings.」

    Following a March 2023 board resolution and approval at the shareholders’ meeting in April 2023, an additional measure progressed to reduce capital and capital reserves by ¥4,435,693,788 each, allocate ¥8,871,387,576 to offset the deficit, and reduce retained earnings carried forward to ¥0.
  9. FY2023-Q2AchievedAnnual report

    「Based on a resolution at the 9th Annual General Meeting of Shareholders held on 27 April 2022, the Company offset the deficit in retained earnings carried forward effective 6 June 2022, reducing capital and capital surplus by ¥3,219.947 million each and increasing retained earnings by ¥6,439.895 million.」

    Effective 6 June 2022, the Company offset the deficit by reducing capital and capital surplus by ¥3,219.947 million each and increasing retained earnings by ¥6,439.895 million. The matter progressed from the previous shareholders’ meeting approval and planning stage to completion.
  10. FY2022AdvancedAnnual report

    「At a meeting of the Board of Directors held on 11 March 2022, the Company resolved to submit a proposal concerning reductions in the amounts of capital and capital reserves and the disposal of retained earnings to the 9th Annual General Meeting of Shareholders held on 27 April 2022. The proposal was approved and adopted at that meeting.」

    Regarding the deficit offset, an additional measure was approved at the shareholders’ meeting to reduce capital and capital reserves by approximately ¥3.22 billion each and transfer approximately ¥6.44 billion in other capital surplus to retained earnings carried forward, reducing retained earnings carried forward to ¥0.
  11. FY2022-Q2AchievedAnnual report

    「Based on a resolution at the 8th Annual General Meeting of Shareholders held on 28 April 2021, the Company offset the deficit in retained earnings carried forward effective 9 June 2021, reducing capital and capital surplus by ¥1,488.493 million each and increasing retained earnings by ¥2,976.986 million.」

    Effective 9 June 2021, the deficit in retained earnings carried forward was offset through reductions in capital and capital surplus. The matter progressed from the previous approval and planned stage to completion.
  12. FY2021AdvancedAnnual report

    「At a meeting of the Board of Directors held on 17 March 2021, the Company resolved to submit a proposal concerning reductions in the amounts of capital and capital reserves and the disposal of retained earnings to the 8th Annual General Meeting of Shareholders held on 28 April 2021. The proposal was approved and adopted at that meeting.」

    Following the previous deficit offset, an additional deficit offset through reductions in capital and capital reserves and the disposal of retained earnings was approved at the shareholders’ meeting. The planned effective date is 9 June 2021, and the plan calls for retained earnings carried forward to be reduced to ¥0.
  13. FY2021-Q2AchievedAnnual report

    「Based on a resolution at the 7th Annual General Meeting of Shareholders held on 28 April 2020, the Company offset the deficit in retained earnings carried forward effective 9 June 2020, reducing capital and capital surplus by ¥2,523.461 million each and increasing retained earnings by ¥5,046.923 million.」

    Effective 9 June 2020, the Company offset the deficit in retained earnings carried forward by reducing capital and capital surplus by ¥2,523.461 million each and increasing retained earnings by ¥5,046.923 million.
  14. FY2020AdvancedAnnual report

    「The Company will reduce the amounts of capital and capital reserves to reduce its tax burden, offset the deficit to strengthen its financial position, and secure flexibility in its capital policy, including future shareholder returns through dividends and share repurchases, by reducing capital and capital reserves and disposing of retained earnings.」

    Following the deficit offset in June 2019, a plan to reduce capital and capital reserves to offset the deficit and secure flexibility in capital policy, including shareholder returns, has progressed through a March 2020 board resolution and approval at the shareholders’ meeting in April.
  15. FY2020-Q3RestatedAnnual report

    「As a result of offsetting the deficit in retained earnings carried forward effective 11 June 2019, capital and capital surplus each decreased by ¥4,907.644 million, while retained earnings increased by ¥9,815.288 million.」

    The offsetting of the deficit in retained earnings carried forward through the reduction of capital and capital surplus dated 11 June 2019 has been reconfirmed.
  16. FY2020-Q2First statedAnnual report

    「Based on a resolution adopted at the 6th Annual General Meeting of Shareholders held on 26 April 2019, the company made up the deficit in retained earnings brought forward on 11 June 2019, reducing share capital and capital surplus by ¥4,907.644 million each and increasing retained earnings by ¥9,815.288 million.」

    On 11 June 2019, the company made up the deficit in retained earnings brought forward, reducing share capital and capital surplus by ¥4,907.644 million each and increasing retained earnings by ¥9,815.288 million.
Moved together

"Early launch of SB623 using Japan’s accelerated approval system" moved the same way as this thread, in the same document, in 11 of its 19 moves.

1110101099★123456
  1. ★This thread
  2. 1Early launch of SB623 using Japan’s accelerated approval system11×
  3. 2Establishment of the Manufacturing, Logistics and Sales Framework for SB623 After Commercialization10×
  4. 3SB623 Traumatic Brain Injury Clinical Trial in Japan10×
  5. 4Diversification of Funding Through Stock Market and Bank Financing10×
  6. 5Mass Production of Allogeneic Regenerative Cell Therapies and Securing Product Supply Rights9×
  7. 6Continued investment in research and development9×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for SanBio yet. It last moved in the General Meetings of Shareholders of 2026-03-31: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Eliminating Accumulated Deficits through Reductions in Stated Capital and Capital Reserves | SanBio Company Limited (4592) | Komori